ImmunoGen Reports Recent Progress and First Quarter 2021 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. AMZN
2. INTC
3. COIN
4. RDDT
5. PINS
6. FSLR
7. SYK
8. DASH
9. FND
10. GILD

Go back to ImmunoGen Reports Recent Progress and First Quarter 2021 Financial Results

Immunogen (IMGN) Tops Q1 EPS by 2c, Revenues Miss; Offers 2Q Revenues Outlook

May 10, 2021 6:32 AM EDT

Immunogen (NASDAQ: IMGN) reported Q1 EPS of ($0.17), $0.02 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $15.55 million versus the consensus estimate of $17.73 million.

"During the first quarter, we advanced our portfolio of innovative ADCs and accelerated preparations for two potential product launches next year," said Mark Enyedy, ImmunoGen's President and Chief Executive Officer. "We saw a limited delay in patient enrollment in the pivotal SORAYA trial for our lead program, mirvetuximab soravtansine, which has shifted the anticipated timing of top-line data from the third into the fourth... More